CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Cash flows used in operating activities:
Net loss	$ (148,315)	$ (35,286)	$ (25,635)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Depreciation	361	331	672
Amortization of intangibles and interest accretion of contingent consideration	94,334	32,668	8,004
Amortization of deferred financing costs	2,730	2,333	1,295
Accretion of debt discount	2,286	0	0
Interest accretion of notes receivable	(127)	(292)	(114)
Deferred income tax expense (benefit)	6,746	(11,753)	(22,516)
Gain on sale of investment	0	0	(3,605)
Loss on disposal of software and equipment	19	242	208
Loss on extinguishment of debt	1,112	0	0
Stock compensation expense	5,944	4,686	2,049
Expense for stock options issued in exchange for services	0	119	548
Cancellation of ParaPRO stock options in connection with termination of contract	0	(1,294)	0
Fair market value change in derivative liability	(19,315)	0	0
Fair market value change in contingent consideration and put right	(138)	0	7,556
Gain on contingent consideration and put right	0	0	(16,269)
Issuance of stock for inducement	19,500	0	0
Loss on impairment	24,352	0	19,429
Loss on sale of PML (including impairment)	0	6,659	0
(Increase) decrease in operating assets (net of effect of acquisitions):
Accounts receivable	(17,082)	(18,480)	12,163
Income taxes	(4,145)	(6,592)	642
Inventory	444	1,880	7,406
Prepaid expenses and other assets	2,471	(2,144)	(2,180)
Increase (decrease) in operating liabilities (net of effect of acquisitions):
Accounts payable and accrued expenses	6,682	12,161	(3,398)
Accrued allowances	10,074	18,318	(3,075)
Interest payable	2,291	10,012	100
Other liabilities	(4,973)	(4,672)	10,189
Net cash (used in) provided by operating activities	(14,749)	8,896	(6,531)
Cash flows from investing activities:
Acquisitions	(87,986)	(254,950)	(310)
Proceeds from sale of investment	0	0	4,605
Payments received on notes receivable	4,850	4,850	0
Proceeds from sale of PML	0	1,137	0
Proceeds from sale of certain Cypress assets	0	175	19,588
Proceeds from sale of equipment	0	43	31
Purchase of software and equipment	(1,212)	(1,177)	(528)
Net cash (used in) provided by investing activities	(84,348)	(249,922)	23,386
Cash flows from financing activities:
Proceeds from issuance of Convertible Notes	130,000	65,000	0
Cash acquired in connection with acquisition of Somaxon	0	0	2,881
Payments on contracts payable	0	(2,500)	(1,700)
(Payments) proceeds from Treximet Secured Notes	(10,013)	220,000	0
Net drawdowns (payments) on credit facilities	7,655	(9,515)	(25,153)
Payments for financing costs	(5,349)	(14,149)	0
Payment of consent fee	(2,150)	0	0
Payments on mortgages and capital leases	(44)	(46)	(144)
Proceeds from issuance of common stock, net of tax and costs	395	2,149	262
Tax benefit on stock-based awards	0	404	(147)
Shares withheld for the payment of taxes	(117)	(1,109)	(230)
Net cash provided by (used in) financing activities	120,377	260,234	(24,231)
Net increase (decrease) in cash and cash equivalents	21,280	19,208	(7,376)
Cash and cash equivalents, beginning of period	34,855	15,647	23,023
Cash and cash equivalents, end of period	$ 56,135	$ 34,855	$ 15,647